Abstract: The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stable solution formulation of an IgG1 antibody that specifically binds to insulin-like growth factor-I receptor. In another embodiment, the invention provides methods of stabilization of IgG1 antibody that specifically binds to insulin-like growth factor-I receptor comprising lyophilizing an aqueous formulation of the antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration.

Abstract: In one embodiment, the present invention provides a stable lyophilized formulation comprising an anti-EGFR antibody, preferably cetuximab; lactobionic acid; and a buffer, preferably histidine. In one preferred embodiment, the present invention provides a stable lyophilized formulation comprising about 50 mg/mL to about 140 mg/mL of ERBITUX?, about 0.125% lactobionic acid, about 25 mM histidine buffer at a pH of about 6.0, about 0.005% Tween 80, and about 1.875% glycine.

Abstract: The present invention provides formulations and methods for the stabilization of antibodies. In one embodiment, the invention provides the stabile formulation of antibodies that are prone to non-enzymatic fragmentation at the hinge region. In a further embodiment, the invention provides methods of stabilization of antibodies comprising lyophilizing an aqueous formulation of an antibody. The formulations can be lyophilized to stabilize the antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration. In one embodiment, the present invention provides methods of stabilization of anti-VEGFR antibodies comprising lyophilizing an aqueous formulation of an anti-VEGFR antibody. The formulations can be lyophilized to stabilize the anti-VEGFR antibodies during processing and storage, and then the formulations can be reconstituted for pharmaceutical administration.

Abstract: A bioactive fraction obtained from Xylocarpus that is useful for the treatment of diabetes and dyslipidemia. This fraction can be provided in a pharmaceutical composition that is useful as antidiabetic and antidyslipidemic agent, or can be used in a method of treating diabetes and dyslipidemia in a subject. Also, a process for the preparation of bioactive fraction from Xylocarpus. Novel isomeric xyloccensins and the preparation of such compounds. Also, pharmaceutical compositions comprising a therapeutically effective amount of such novel isomeric xyloccensins optionally along with one or more pharmaceutically acceptable carriers, additives, lubricant and diluents and the use of such pharmaceutical compositions in a method for treating dyslipidemia.

Abstract: The present invention provides a method of monitoring a predetermined type of molecule conveyed through a gaseous medium. The method comprises that step of positioning at least one electronic detector for detecting the predetermined type of molecule. The method also comprises the steps of measuring molecules of the predetermined type to detect a quantity of the molecules and producing electronic data associated with the quantity of molecules. The method further comprises the step of monitoring changes in the electronic data so as to provide information that can be used to control a source of the predetermined type of molecule.

Abstract: The present invention provides a detector for detecting molecules conveyed through a gaseous medium. For example, the molecules may be emitted from sewage, meat production plants, or detection of the molecules may give information about a state of health of a human or an animal. The detector comprises sensors which have sensing surfaces. Each sensing surface has an electrical property that changes in response to the molecules when the molecules are coupled to the sensing surface so that the coupled molecules can be sensed by detecting the changed electrical property. The sensors are sensitive for a sulphur compound and for an organic compound. The present invention also provides a method of fabricating a detector for detecting molecules conveyed through the gaseous medium.

Abstract: The present invention provides novel substituted flavone derivatives which exhibit anti-hyperglycemic and antidyslipedemic activity. The invention also provides a method for controlling type II diabetes and associated hyperlipidemic conditions in a mammal by administering compound of the present invention and compositions containing these derivatives.

Abstract: The present invention provides novel substituted chalcone derivatives which exhibit anti-hyperglycemic and anti-dyslipedemic activity. The invention also provides a method for treating type II diabetes and associated hyperlipidemic conditions in a mammal by administering the compounds of the present invention and compositions containing these derivatives.

Abstract: The present invention provides a novel saponin tigogenin penta glycoside isolated from the aerial parts of Chlorophytum nimonii and a process for the isolation thereof as well as its use in anti-hyperglycemic and hypolipidemic activities.

Abstract: This invention relates to novel {overscore (&ohgr;)}-substituted-naphthyloxy-amino alkanes, their preparation and use as antihyperglycemic agents and for the treatment and prevention of cardiovascular disorders (CVS) such as lipid lowering effects.